Viatris Expects First Interchangeable Biosimilar Designations For Insulins In July
Firm Expecting Landmark Nods For Both Glargine And Aspart
Amid continued debate over biosimilar interchangeability in the US, Viatris has said it expects to pick up the first such approvals later this year with the company’s insulin glargine and insulin aspart biosimilar products.
